drugset / Trial / NCT01724580

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

NCT01724580 ↗

Expanded access Approved for marketing Eli Lilly and Company

Summary

The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule — Oral